Clinical Trial News and Research

RSS

Soligenix second quarter revenues decrease to $406,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2011.

12 Aug 2011

Sinovac second quarter sales increase 52.5% to $15.7 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter financial results for the period ended June 30, 2011.

12 Aug 2011

New technique can help develop HIV vaccines

Researchers have traced in detail how certain powerful HIV neutralizing antibodies evolve, a finding that generates vital clues to guide the design of a preventive HIV vaccine, according to a study appearing in Science Express this week.

12 Aug 2011

Second annual CNS Summit to shape the future of drug development

Segal Institute for Clinical Research, a consortium of CNS and women's health research sites, is preparing to again be actively involved in CNS Summit this coming fall.

12 Aug 2011

InVivo Therapeutics reports net loss of $1,370,000 for second quarter 2011

InVivo Therapeutics Holdings Corp., a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported financial results for the three and six months ended June 30, 2011 and provided a business update.

11 Aug 2011

New treatment uses lasers to stimulate stem cells and reduce heart scarring

After a heart attack or stroke, heart scarring can lead to dangerously paper-thin heart walls and a decreased ability to pump blood through the body. Although the heart is unable to completely heal itself, a new treatment developed at Tel Aviv University uses laser-treated bone marrow stem cells to help restore heart function and health.

11 Aug 2011

Aeras, OETC announce initiation of new TB vaccine Phase IIb trial in patients with HIV

Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) announce today the start of a Phase IIb proof-of-concept efficacy trial of a new investigational tuberculosis (TB) vaccine that involves people living with the human immunodeficiency virus.

11 Aug 2011

Bristol-Myers Squibb, GNS collaborate to identify biomarkers in immuno-inflammation

GNS Healthcare, Inc., (GNS) the leading healthcare analytics company focused on enabling personalized medicine to improve human health, today announced that it has entered into a collaboration with Bristol-Myers Squibb Company focused on the discovery of novel disease biology and biomarkers in the area of immuno-inflammation.

11 Aug 2011

Gastroenterology journal publishes results of Lexicon LX1031 Phase 2 trial in IBS

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that results from the Phase 2 clinical trial of LX1031 in patients with non-constipating irritable bowel syndrome (IBS) were published earlier this week in the August 2011 edition of the journal Gastroenterology.

11 Aug 2011

BELLUS Health second quarter revenues increase to $719,000

BELLUS Health Inc. reported today its financial results for the second quarter ended June 30, 2011.

10 Aug 2011

SANUWAVE second quarter revenues increase 40%

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today reported financial results for the three and six months ended June 30, 2011 and provided a business update.

10 Aug 2011

First renal denervation with Medtronic Symplicity Catheter System performed in Latin America

Medtronic today announced the first use in Latin America of renal denervation with the Medtronic Symplicity Catheter System™ to treat a patient with resistant hypertension, which is defined as high blood pressure despite treatment with three or more anti-hypertensive medications. Hypertension is an especially dangerous disease affecting hundreds of millions of people worldwide.

From Medtronic 10 Aug 2011

Hydros-TA therapy provides next generation of osteoarthritis relief

Osteoarthritis (OA) is the most common form of arthritis, affecting roughly 10% of Canadians. This degradation of the joints is painful and crippling, especially when it affects the knee. Although there are viable OA treatment options, they are short-lived and can have serious side-effects.

10 Aug 2011

Positive data from Lexicon LX1032 Phase 2 study on carcinoid syndrome

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line proof-of-concept data from its recently completed Phase 2 study in carcinoid syndrome with LX1032, telotristat etiprate. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract.

9 Aug 2011

GTx reports revenue of $1.6 million for second quarter 2011

GTx, Inc. today reported financial results for the second quarter of 2011. The net loss for the quarter ended June 30, 2011 was $10.7 million compared with a net loss of $12.9 million for the quarter ended June 30, 2010.

9 Aug 2011

Medidata Solutions second quarter net revenues increase 25% to $50.2 million

Medidata Solutions, a leading global provider of SaaS-based clinical technology solutions that enhance the efficiency of clinical development, today announced its financial results for the second quarter 2011, as well as provided financial guidance for the third quarter and full year 2011.

9 Aug 2011

Engineered T cells can eradicate deadly human ovarian cancer in immune-deficient mice

In a recent issue of Cancer Research, Daniel J. Powell, Jr., PhD, a research assistant professor of Pathology and Laboratory Medicine and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, showed for the first time that engineered human T cells can eradicate deadly human ovarian cancer in immune-deficient mice.

9 Aug 2011

Thomson Reuters, ESMO launch new education portal for oncologists

A unique scientific information and education portal designed to help oncologists keep up to date with the latest research and clinical information in their field has been launched by the European Society for Medical Oncology (ESMO) in partnership with Thomson Reuters, the global information and news organization.

9 Aug 2011

PHT total revenues increase 10% for first half of 2011

PHT Corporation completed its most successful Q2 in company history on June 30, 2011. The strong, outstanding results reflect the growing worldwide adoption of its market-leading ePRO Systems.

9 Aug 2011

Lexicon's second quarter revenues decrease 55% to $0.6 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2011.

9 Aug 2011